149 related articles for article (PubMed ID: 24825411)
1. Steady-state pharmacokinetics of darunavir/ritonavir and pitavastatin when co-administered to healthy adult volunteers.
Yu CY; Campbell SE; Sponseller CA; Small DS; Medlock MM; Morgan RE
Clin Drug Investig; 2014 Jul; 34(7):475-82. PubMed ID: 24825411
[TBL] [Abstract][Full Text] [Related]
2. Effects of steady-state lopinavir/ritonavir on the pharmacokinetics of pitavastatin in healthy adult volunteers.
Morgan RE; Campbell SE; Suehira K; Sponseller CA; Yu CY; Medlock MM
J Acquir Immune Defic Syndr; 2012 Jun; 60(2):158-64. PubMed ID: 22627182
[TBL] [Abstract][Full Text] [Related]
3. Lack of pharmacokinetic interactions between pitavastatin and efavirenz or darunavir/ritonavir.
Malvestutto CD; Ma Q; Morse GD; Underberg JA; Aberg JA
J Acquir Immune Defic Syndr; 2014 Dec; 67(4):390-6. PubMed ID: 25202920
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two-panel, two-way, two-period, randomized trial.
Kakuda TN; DeMasi R; van Delft Y; Mohammed P
HIV Med; 2013 Aug; 14(7):421-9. PubMed ID: 23441978
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of darunavir/ritonavir and ketoconazole following co-administration in HIV-healthy volunteers.
Sekar VJ; Lefebvre E; De Pauw M; Vangeneugden T; Hoetelmans RM
Br J Clin Pharmacol; 2008 Aug; 66(2):215-21. PubMed ID: 18460033
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjects.
Jackson A; Moyle G; Dickinson L; Back D; Khoo S; Taylor J; Gedela K; Abongomera G; Gazzard B; Boffito M
Antivir Ther; 2012; 17(1):19-24. PubMed ID: 22267465
[TBL] [Abstract][Full Text] [Related]
7. Effect of repeated doses of darunavir plus low-dose ritonavir on the pharmacokinetics of sildenafil in healthy male subjects: phase I randomized, open-label, two-way crossover study.
Sekar V; Lefebvre E; De Marez T; De Pauw M; De Paepe E; Vangeneugden T; Hoetelmans RM
Clin Drug Investig; 2008; 28(8):479-85. PubMed ID: 18598093
[TBL] [Abstract][Full Text] [Related]
8. Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individuals.
Jackson A; Watson V; Back D; Khoo S; Liptrott N; Egan D; Gedela K; Higgs C; Abbas R; Gazzard B; Boffito M
J Acquir Immune Defic Syndr; 2011 Dec; 58(5):450-7. PubMed ID: 21926632
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of multiple-dose darunavir in combination with low-dose ritonavir in individuals with mild-to-moderate hepatic impairment.
Sekar V; Spinosa-Guzman S; De Paepe E; Stevens T; Tomaka F; De Pauw M; Hoetelmans RM
Clin Pharmacokinet; 2010 May; 49(5):343-50. PubMed ID: 20384396
[TBL] [Abstract][Full Text] [Related]
10. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
Garvey L; Latch N; Erlwein OW; Mackie NE; Walsh J; Scullard G; McClure MO; Dickinson L; Back D; Winston A
Antivir Ther; 2010; 15(2):213-8. PubMed ID: 20386076
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of darunavir in fixed-dose combination with cobicistat compared with coadministration of darunavir and ritonavir as single agents in healthy volunteers.
Kakuda TN; Opsomer M; Timmers M; Iterbeke K; Van De Casteele T; Hillewaert V; Petrovic R; Hoetelmans RM
J Clin Pharmacol; 2014 Aug; 54(8):949-57. PubMed ID: 24644095
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of a three-way drug interaction between danoprevir, ritonavir and the organic anion transporting polypeptide (OATP) inhibitor ciclosporin.
Brennan BJ; Moreira SA; Morcos PN; Navarro MT; Asthappan J; Goelzer P; Weigl P; Smith PF
Clin Pharmacokinet; 2013 Sep; 52(9):805-13. PubMed ID: 23712757
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of darunavir at 900 milligrams and ritonavir at 100 milligrams once daily when coadministered with efavirenz at 600 milligrams once daily in healthy volunteers.
Soon GH; Shen P; Yong EL; Pham P; Flexner C; Lee L
Antimicrob Agents Chemother; 2010 Jul; 54(7):2775-80. PubMed ID: 20385850
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of darunavir/ritonavir and rifabutin coadministered in HIV-negative healthy volunteers.
Sekar V; Lavreys L; Van de Casteele T; Berckmans C; Spinosa-Guzman S; Vangeneugden T; De Pauw M; Hoetelmans R
Antimicrob Agents Chemother; 2010 Oct; 54(10):4440-5. PubMed ID: 20660678
[TBL] [Abstract][Full Text] [Related]
15. Co-administration of raltegravir reduces daily darunavir exposure in HIV-1 infected patients.
Cattaneo D; Gervasoni C; Cozzi V; Baldelli S; Fucile S; Meraviglia P; Landonio S; Boreggio G; Rizzardini G; Clementi E
Pharmacol Res; 2012 Feb; 65(2):198-203. PubMed ID: 21958880
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous pharmacogenetics-based population pharmacokinetic analysis of darunavir and ritonavir in HIV-infected patients.
Moltó J; Xinarianos G; Miranda C; Pushpakom S; Cedeño S; Clotet B; Owen A; Valle M
Clin Pharmacokinet; 2013 Jul; 52(7):543-53. PubMed ID: 23494984
[TBL] [Abstract][Full Text] [Related]
17. Bioavailability and bioequivalence of a darunavir 800-mg tablet formulation compared with the 400-mg tablet formulation.
Kakuda TN; Leopold L; Timmers M; Van De Casteele T; Hillewaert V; Tomaka FL; Hoetelmans RM
Int J Clin Pharmacol Ther; 2014 Sep; 52(9):805-16. PubMed ID: 25109510
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of once-daily darunavir-ritonavir and atazanavir-ritonavir over 72 hours following drug cessation.
Boffito M; Jackson A; Amara A; Back D; Khoo S; Higgs C; Seymour N; Gazzard B; Moyle G
Antimicrob Agents Chemother; 2011 Sep; 55(9):4218-23. PubMed ID: 21709075
[TBL] [Abstract][Full Text] [Related]
19. The effect of different meal types on the pharmacokinetics of darunavir (TMC114)/ritonavir in HIV-negative healthy volunteers.
Sekar V; Kestens D; Spinosa-Guzman S; De Pauw M; De Paepe E; Vangeneugden T; Lefebvre E; Hoetelmans RM
J Clin Pharmacol; 2007 Apr; 47(4):479-84. PubMed ID: 17389557
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic Evaluation of Darunavir Administered Once or Twice Daily in Combination with Ritonavir or the Three-Direct-Acting Antiviral Regimen of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults Coinfected with Hepatitis C and Human Immunodeficiency Viruses.
King JR; Khatri A; Trinh R; Viani RM; Ding B; Zha J; Menon R
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27919899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
